Advances in Anticancer Agent, 2nd Edition
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 1967
Special Issue Editors
Interests: natural products; bioactive compounds; terpenes; phenolics; plant derived compounds; medicinal plants; natural products chemistry; mass spectrometry; multidrug resistance; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals
Interests: drug design; anticancer compounds; prodrug chemistry; drug delivery systems
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
According to the World Health Organization, cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2020. The cancer burden could be reduced by avoiding several risk factors, through appropriate screening and early detection and through the clinical treatment of neoplastic diseases. Chemotherapy remains a cornerstone among the several approaches to treatment, even though intrinsic or acquired resistance and metastasis remain major obstacles to a successful cure. In the last two decades, outstanding progress in genetics and molecular biology has prompted the discovery of novel molecular targets. Moreover, major advances in computational and in silico methods, combinatorial chemistry, chemical synthesis and natural products chemistry have provided new leads for the development of novel anticancer drugs. Nevertheless, and despite the vast number of compounds that have reached the stage of preclinical and clinical studies, the research and development of new anticancer agents and therapeutic strategies is a continuous process and constitutes the main subject of this Special Issue of Pharmaceutics. We welcome original or review articles concerning the discovery and development of new anticancer agents obtained from either synthesis or natural sources, and the submission of studies on topics such as drug targeting, drug design, pharmacokinetics, computer-aided drug design, in silico studies, drug repurposing, pharmacodynamics and drug delivery is greatly encouraged.
We look forward to receiving your contributions.
Dr. Noelia Duarte
Dr. Ana Paula Francisco
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- synthetic/natural anticancer agents
- drug design
- targeted therapies
- hybrid compounds
- metastasis
- multidrug resistance
